There is a need for comparative studies to determine which cell types are better candidates to remedy ischemia. Here, we compared human AC133 + cells and multipotent adult progenitor cells (hMAPC) in a mouse model reminiscent of critical limb ischemia. hMAPC or hAC133 + cell transplantation induced a significant improvement in tissue perfusion (measured by microPET) 15 days posttransplantation compared to controls. This improvement persisted for 30 days in hMAPC-treated but not in hAC133 + -injected animals. While transplantation of hAC133 + cells promoted capillary growth, hMAPC transplantation also induced collateral expansion, decreased muscle necrosis/fibrosis, and improved muscle regeneration. Incorporation of differentiated hAC133 + or hMAPC progeny into new vessels was limited; however, a paracrine angio/ arteriogenic effect was demonstrated in animals treated with hMAPC. Accordingly, hMAPC-conditioned, but not hAC133 + -conditioned, media stimulated vascular cell proliferation and prevented myoblast, endothelial, and smooth muscle cell apoptosis in vitro. Our study suggests that although hAC133 + cell and hMAPC transplantation both contribute to vascular regeneration in ischemic limbs, hMAPC exert a more robust effect through trophic mechanisms, which translated into collateral and muscle fiber regeneration. This, in turn, conferred tissue protection and regeneration with longer term functional improvement.
INTRODUCTION
by cell therapy. Unfortunately, clinical trials based on growth factor delivery have not yielded the expected results, thereby exposing the need for alternatives (5, 13) . Peripheral vascular disease (PVD) caused by inadequate blood supply to the limbs is a severe health Evidence indicating that adult vasculogenesis-vessel formation from endothelial progenitor cells (EPC)-is a problem in the Western world, affecting 3-10% of the population above the age of 60 (5) . Therapeutic revascu-process that contributes to therapeutic neovascularization (6) has fueled the interest in the use of this alterna-larization techniques, like laser revascularization, endovascular treatment, or bypass surgery, can in some cases tive paradigm for therapeutic revascularization. Different (stem) cell populations have been tested in restore flow and prevent gangrene formation/amputation. Nevertheless, for many patients, these techniques animals for treatment of hind limb ischemia, like embryonic stem cells (ESC) (10), unselected bone marrow mo-are not applicable due to the diffuse nature or the distal location of the obstructions or coexistence of comorbidi-nonuclear cells (MNC) (17) , peritoneal macrophages (16) , adipose tissue-derived stem cells (ADSC) (26) , ties. For these no-option patients, alternatives have been proposed, mainly focused on the induction of tissue re-mesenchymal stem cells (MSC) (18) , mature endothelial cells (EC) (19, 35) , or EPC (34, 35) . Overall, results have vascularization by angiogenic gene/protein delivery or shown that whereas mature EC transplantation does not prepared from human umbilical cords and muscle biopsies as previously described (3, 15) . Briefly, for SkM iso-induce functional improvement, a variable degree of recovery has been demonstrated when MNC or EPC were lation, human muscle biopsies were minced and digested with trypsin-EDTA (0.5 mg/ml trypsin/0.53 mM EDTA) transplanted. In contrast to earlier reports, more recent mechanistic studies have revealed that the degree of di-and collagenase (1.5 mg/ml) and isolated cells were grown in Ham-F12 media (GIBCO-BRL) supplemented rect effects of stem/progenitor cells on revascularization may be not as robust, and in some cases even negligible with 20% fetal calf serum (FCS) and 1% penicillin/ streptomycin (GIBCO-BRL). HUVEC cells were grown (19) . Nevertheless, as a result of the promising preclinical results, at least 40 clinical trials with (stem) cells in F12K medium (ATCC) supplemented with serum (10%), heparin (0.1 mg/ml), and ECGS (0.03 mg/ml) have already been started in PVD patients (5) . Most of them have evaluated the potential of cord blood cells, and SMC were grown in DMEM high glucose (GIBCO-BRL) supplemented with 10% serum. Cells were grown peripheral blood-derived MNC, or total bone marrow (2). A few clinical trials have been performed using en-under normoxic conditions. riched stem cell populations like CD34 + or AC133 + cells
In Vivo Studies demonstrating a clinical benefit [reviewed in (5, 13) ]. The mean follow-up time in the majority of these studies Surgery. Severe hind limb ischemia was induced unwas rather short, precluding conclusions on longer term der anesthesia (75 mg/kg ketamine/10 mg/kg xylazine) benefits or possible side effects, the latter as reported in in 6-10-week-old male nude Balbc mice by excision of one recent study (22) . the left iliac artery as previously described (25) . The Taking together the existing preclinical and clinical mice were given postoperative analgesia (5 mg/kg ketodata, further studies should primarily focus on defining profen, every day for 3 days). One million cells resusthe type of stem cell that can exert a greater benefit in pended in 30 µl of PBS, or PBS alone were injected in patients with critical limb ischemia as well as identifyfour equal fractions in the adductor and quadriceps reing the mechanism responsible for this effect. In order gion of the left limb, 24 h after surgery. As undifferentito do so, direct comparative studies involving different ated hMAPC express very low levels of MHC-I and are cell types are required. Along this line, we recently demthus sensitive to natural killer (NK) cell-mediated clearonstrated the superior effect of murine multipotent adult ance (32), all mice were intraperitoneally injected with progenitor cells (mMAPC) compared to unfractionated 20 µl of a specific anti-NK antibody (28) (anti-asialo murine bone marrow cells in a mild hind limb ischemia GM1 antibody; Wako Chemicals) 1-2 h before transmodel, reminiscent of intermittent claudication (4) . In plantation and every 10 days thereafter. Mice were the current study, we tested the potential of human housed in specific pathogen-free conditions and all pro-MAPC (hMAPC) in a severe model of limb ischemia cedures were performed according to the guidelines of (resembling critical limb ischemia) and compared it with the Institutional Animal Care and Use Committee of the human AC133 + cells, which have already been used in University of Navarra. clinical trials. We also compared the main mechanisms Live Imaging and Assessment of Limb Perfusion. of action of both cell types.
Limb perfusion assessment was performed by microPET MATERIALS AND METHODS as described by our group (25) . Briefly, microPET imaging was performed 10 min after 13 N-ammonia injec-Cell and Tissue Processing tion 1, 7, 15, and 30 days after surgery. For quantitative Human bone marrow, muscle biopsies, and umbilical analysis and comparisons among subjects, evaluation of cord blood (UCB) cells were obtained after informed perfusion in both hind limbs was carried out as follows: consent from donor or mother according to the guideregions of interest (ROIs) were drawn on coronal 1-mmlines from the Committee on the Use of Human Subjects thick microPET images over the hind limbs, and activity in Research from the Clínica Universitaria, Pamplona.
concentration per area unit calculated as a measurement UCB mononuclear cells were separated by Ficoll Hyof perfusion. The ratio between left (ischemic) and right paque centrifugation (specific gravity, 1077; Sigma, St.
(nonischemic) hind limbs was used in all cases for com-Louis, MO, USA) and hAC133 + cells were selected usparisons and obtained data were exported to the PMOD ing micromagnetic beads (Miltenyi Biotec, Germany) software package for quantification. with autoMACS columns (Miltenyi Biotec) as described (3) . More than 90% cell purity was obtained after col-Histological Analysis umn selection. hMAPC were obtained according to published protocols (3, 4) . Primary human umbilical vein en-At sacrifice (day 15 and day 30), mice were anesthetized with 60 mg/kg Nembutal and perfused with Tris-dothelial cells (HUVEC), umbilical arterial smooth muscle cells (SMC), and skeletal myoblasts (SkM) were buffered saline (TBS)-adenosine and followed by zinc-paraformaldehyde. Following dissection, muscles were were seeded in 96-well plates at a density of 10 3 cells/ cm 2 (HUVEC) or 5,000 cells/cm 2 (SMC and SkM) and postfixed 24 h and divided in two equal pieces to be processed for paraffin embedding. H&E and Sirius red cultured under hypoxic conditions (1% O 2 ) in the presence of CM, NCM, or in normal cell culture conditions stainings were performed as described (3) . Those areas with presence of fat cells replacing muscle fibers, in-(CCM) (20% O 2 and cell culture media) during 24 h for HUVEC and 72 h for SMC and SkM cells. For this flammatory infiltrates, or "ghost" cells (muscle cells without nucleus) were considered necrotic areas. For im-assay, no serum was added to the CM. The degree of cell apoptosis was measured by an ELISA kit that quan-munofluorescence and immunohistochemistry, antibodies against α-smooth muscle actin (α-SMC, unconju-tifies the presence of oligonucleosomal fragments (Roche Applied Science, Barcelona, Spain). The apopto-gated, DAKO; or Cy3 or FITC conjugated, Sigma), human CD31 (DAKO or Pharmingen), UEA lectin (bio-sis control corresponds to cells cultured under hypoxia and NCM. Under this condition apoptosis was clearly tin, TRITC, or FITC, conjugated; Sigma), mouse BS-I lectin (Sigma), human vimentin (DAKO), and desmin detected and considered 100%. The rest of the samples were referred to that value, in order to determine the (DAKO) were used as primary antibodies. Secondary antibodies coupled to FITC or peroxidase enzyme were degree of "protection" conferred by the conditioned media. Four independent experiments were performed on purchased from Molecular Probes. For quantification, analyses were done on cross sections with regular inter-cells seeded in quadruplicate. vals spanning 2 mm. When technically feasible, entire RNA Isolation, qRT-PCR, and ELISA cross sections were evaluated on lower power field im-Total RNA from hAC133 + and hMAPC was exages, or when higher magnification was required several tracted using the RNAeasy minikit (Qiagen). mRNA (usually 3-4 per section) randomly chosen higher power was reverse transcribed using Superscript III Reverse fields covering a large part of each cross section were Transcriptase (Invitrogen) and cDNA underwent 40 cyanalyzed. Pictures for morphometric analysis were taken cles of amplification (ABI PRISM 7700, Perking Elmer/ using a Zeiss Axio Imager connected to an Axiocam Applied Biosystems). SYBR Green Universal Mix PCR MRc5 camera (Zeiss, Zaventem, Belgium) and analysis reaction buffer (Applied Biosystems) was used for quanwas performed using Image J, KS300 (Leica, Brussels, tification, normalizing data using GAPDH as housekeep-Belgium).
ing gene. Cytokine levels present in hMAPC or hAC133 + conditioned and nonconditioned medias were quantified In Vitro Proliferation and Apoptosis Assays by ELISA. For human VEGF, bFGF, and Ang-2, ELISA Proliferation. hMAPC were cultured in MAPC mekits were purchased from R&D Systems and ELISA dium (3) with 2% FCS but without cytokines at a denprocedures were followed according to the manufactursity of 17,500 cells/cm 2 , and hAC133 + cells were culer's instructions. tured in DMEM high glucose supplemented with 2%
Statistical Analysis FCS at a density of 10 5 /cm 2 . Conditioned media (CM) were collected after 48 h. Corresponding media incu-All data are expressed as mean ± SEM or median bated without cells for 48 h served as controls [noncon-(Q1; Q3). Comparisons for repeated measurements were ditioned media (NCM)]. Early passages of HUVEC, performed by ANOVA or Kruskal-Wallis tests. Shapiro-SMC, or SkM were seeded in 24-well plates at a cell Wilk test was used to verify that the data had a Gaussian density of 1,250 cells/cm 2 (HUVEC and SkM) or 625 distribution, which justifies the use of a parametric test. cells/cm 2 (SMC), respectively, and cultured in the pres-Tukey, Tukey's b, and Tamhane's T2 post hoc tests ence of hMAPC or hAC133 + CM or NCM. In order to were performed after ANOVA and U-Mann-Whitney 1: obtain the same cell concentration as hMAPC, hAC133 + 1 with signification correction by Bonferroni's method CM was previously diluted and all media were supplefor the nonparametric tests. Statistical analysis was permented with extra serum to reach a 6% FCS concenformed with Instat 3.0 software and differences were tration. After 72 h, the number of viable cells was considered statistically significant when p < 0.05. quantified by a luminiscent cell viability assay (Cell RESULTS Titer-Glo TM , Promega, USA) following the manufacturer's protocol. Four independent experiments were per-hMAPC Have a More Durable Effect on Limb formed and every cell type grown in CM or NCM was Reperfusion Than hAC133 + Cells seeded in quadruplicate.
The revascularization potential of hAC133 + cells and hMAPC was compared in a severe ischemia model in-Apoptosis. CM from hMAPC and hAC133 + were collected as described before, after 12-h culture in non-duced by iliac artery excision. After 24 h, such injury caused a dramatic decrease in blood perfusion (ϳ70%) serum-containing media. Endothelial and skeletal cells in the ischemic limb ( Fig. 1 ). By day 15, PBS-injected Unlike hAC133 + Cells, hMAPC Significantly Improve Muscle Viability and Regeneration animals presented a spontaneous recovery in blood flow (54 ± 3% at 15 days vs. 23 ± 3% at 24 h). In comparison
In a next series of analyses, we determined whether with this group, a significantly greater recovery was dethere was a correlation between revascularization and tected in the animals transplanted either with hAC133 + the degree of tissue damage or regeneration, by analyzcells or hMAPC (PBS: 54 ± 3%; hAC133 + : 74 ± 7%, p < ing muscle necrosis, fibrosis, and regeneration 30 days 0.05; hMAPC: 64 ± 4%, p < 0.05). Importantly, 30 days posttransplantation. Necrosis and fibrosis were signifiposttransplantation, while animals treated with hMAPC cantly lower in the hMAPC-treated but not in hAC133 +presented a significantly higher blood flow, perfusion treated animals, compared to PBS [% necrosis: 31 ± 5 recovery was no longer significantly different from conin PBS; 27 ± 5 in hAC133 + , P = NS and 12 ± 5 in trols in the animals treated with hAC133 + (PBS: 66 ± hMAPC, p < 0.05; hMAPC vs. hAC133 + , p < 0.05 ( Fig.  3% ; hAC133 + cells: 73 ± 5%, p = NS; hMAPC: 77 ± 3A-D); % fibrosis: 15 ± 2 in PBS; 12 ± 3 in hAC133 + , 3%, p < 0.05) ( Fig. 1 ), suggesting that hMAPC exerted P = NS and 8 ± 2 in hMAPC, p < 0.05; hMAPC vs. a more robust and prolonged effect on reperfusion than hAC133 + , NS ( Fig. 3E-H) ]. Moreover, also by day 15, hAC133 + cells.
necrosis and fibrosis were significantly lower in the hMAPC-treated animals than in the hAC133 + -treated hMAPC and hAC133 + Cells Have a Differential Effect ones (data not shown). Finally, we evaluated the degree on Blood Vessel Growth of muscle regeneration (myogenesis), defined by the We first examined whether the different effects on presence of fibers with strong positivity for desmin (14) . reperfusion could be explained by histological assess-Unlike hAC133 + cell-injected muscles, at day 30, ment of blood vessel growth. In the ischemic adductor hMAPC-treated muscles showed a statistically signifiregion, vascular expansion occurs by a combination of cant higher expression of this marker compared with three mechanisms: vasculogenesis (vascular precursor nontreated limbs [% desmin area: 1.15 ± 0.15 in PBS; incorporation into growing vessels), angiogenesis (capil-1.51 ± 0.13 in hAC133 + , p = NS; 1.71 ± 0.17 in hMAPC, lary growth), and adaptive arteriogenesis (collateral p < 0.05; hMAPC vs. hAC133 + , NS) ( Fig. 3I-L) , a difexpansion). First, direct contribution of hMAPC or ference that was already detected at day 15 (data not hAC133 + vascular progeny was studied at 30 days after shown). These results suggest a unique capacity of surgery. As we have previously reported, direct contri-hMAPC to contribute to muscle regeneration compared bution of hMAPC to both EC (human specific CD31 to hAC133 + cells. and UEA positive) and SMC layers (human vimentin hMAPC Secrete Factors That Protect Against and α-actin double positive) of the newly formed vessels Apoptosis and Stimulate Proliferation was confirmed in the adductor region. However, this contribution was limited ( Fig. 2A-C) (4) . On the other Because direct contribution to vessels was limited, we hypothesized that the beneficial effects on revascu-hand, hAC133 + cells also contributed to the EC lineage, although they did not differentiate into SMC (Fig. 2D larization and muscle regeneration were due to trophic effects on endogenous cells. Therefore, we measured F). The remaining hAC133 + cell fraction at 30 days was too low to allow for reliable quantification. Thus, for growth factor secretion and performed experiments with CM on vascular and muscular cells. Quantification by both cell types, vascular incorporation was low, which makes it unlikely that vasculogenesis was the main re-qRT-PCR showed a higher expression of proangiogenic and arteriogenic factors (VEGF 165 , bFGF, and PlGF) in vascularization mechanism.
Next, we quantified the effect of cell transplantation hMAPC versus hAC133 + cells (hMAPC vs. hAC133 + cells: % expression vs. universal RNA: VEGF 165 : 236 ± on capillary growth and collateral expansion. Both cell types had a significant effect on both parameters; how-144 vs. 8.4 ± 0.4; PlGF: 1828 ± 2407 vs. 10 ± 5; bFGF: 452 ± 106 vs. 12 ± 17). Protein secretion, determined by ever, they had a differential effect on these processes. While hAC133 + cells mainly affected capillary growth ELISA, confirmed the higher secretion of VEGF 165 , bFGF, and PlGF by hMAPC (hMAPC vs. hAC133 + (small CD31 + vessels/mm 2 : 290 ± 36 in PBS; 759 ± 96 in hAC133 + , p < 0.01 and 493 ± 45 in hMAPC, p < cells: pg/10 5 cells: VEGF 165 : 8066 ± 636 vs. undetectable; bFGF: 20 ± 3 vs. undetectable; PlGF: 11 ± 5 vs. 0.01; hMAPC vs. hAC133 + , p < 0.05) ( Fig. 2G-J) , the effect of hMAPC on collateral expansion was much undetectable).
To determine whether the release of growth factors more apparent (α-actin-coated vessel area %: 0.32 ± 0.10 in PBS; 0.59 ± 0.10 in hAC133 + , p < 0.05 and 0.72 ± by the transplanted cells could be responsible for the observed beneficial effect on vascular/muscular regener-0.14 in hMAPC, p < 0.05; hMAPC vs. hAC133 + , p < 0.05) ( Fig. 2K-N) .
ation in vivo, we analyzed the potential of hAC133 + cell- or hMAPC-derived CM to induce proliferation and/or to hMAPC CM with a trend towards statistical significance (data not shown); however, unlike hAC133 + CM, inhibit apoptosis of vascular/muscular cells. Culture of EC and SMC in the presence of hMAPC but not hMAPC CM exerted a potent antiapoptotic effect on SkM when these were exposed to hypoxia or serum dep-hAC133 + CM induced a significant increase in their proliferation rate in comparison with the NCM (EC prolif-rivation [% SkM apoptosis vs. NCM (100%): 3 ± 3 for CCM, p < 0.01, 97 ± 16 for hAC133 + CM, p = NS, and eration relative to NCM: 1.0 ± 0.2-fold for hAC133 + CM, p = NS and 6.5 ± 0.8-fold for hMAPC-CM, p < 20 ± 8 for hMAPC CM, p < 0.01] (Fig. 4C) . Thus, hMAPC, but not hAC133 + cells, had a beneficial effect 0.05; SMC proliferation relative to NCM: 0.9 ± 0.1-fold for hAC133 + CM, p = NS and 1.4 ± 0.2-fold for on vascular/muscular cell proliferation and/or survival through paracrine effects. hMAPC-CM, p < 0.05) (Fig. 4A, B . In addition, while hMAPC-CM almost completely abrogated the apoptosis DISCUSSION induced by hypoxia (1% O 2 ) and serum deprivation in the EC and SMC, no significant protection was observed
The already high incidence of PVD will further increase due to a growing number of patients that carry when cells were cultured in the presence of hAC133 + CM [% EC apoptosis vs. NCM (100%): 7 ± 3 for CCM risk factors (e.g., diabetes, hypertension) predisposing them for developing PVD. At the same time, for many (normoxia and 10% FCS), p < 0.01, 84 ± 8 for hAC133 + CM, p = NS and 35 ± 12 for hMAPC-CM, p < 0.05; % of these patients these risk factors may limit the therapeutic options for revascularization. The demonstration SMC apoptosis vs. NCM (100%): 18 ± 1 for CCM, p < 0.01, 87 ± 5 for hAC133 + CM, p = NS and 21 ± 10 for of postnatal vasculogenesis (6) fueled a boost in preclinical studies as well as a rapid clinical translation of this hMAPC CM, p < 0.05] (Fig. 4C) . Finally, the effect of CM on SkM proliferation was moderate in the case of concept. However, many issues need to be resolved be- fore cell transplantation becomes routine practice for like hAC133 + cells, hMAPC stimulated muscle regeneration to a statistically significant extent in this severe PVD treatment. In this context, we performed a recent study in which we compared murine unfractionated bone ischemic setting. We chose to compare hMAPC with hAC133 + cells marrow cells with mMAPC in a model reminiscent of intermittent claudication, a milder PVD form (4) . The because the latter are already used in clinical PVD trials (8, 9, 20) . AC133 (or prominin-1) is a surface antigen ex-current study was intended to further extend these studies in order to increase our understanding of the role of pressed on precursors with hematopoietic, neuronal, endothelial, or myogenic potential (30) . Our study is not stem cells in ischemic disease: by comparing two populations of human-derived cells; by following up the ef-the first to evaluate these cells in a preclinical PVD model; however, in most of the studies, their potential fects of transplantation for longer term; by testing the cells in a severe limb ischemia model, reminiscent of was not compared to that of other stem cell sources and the study settings were also different (7, 27, 31) . Unlike critical limb ischemia (which is the main target for cell therapy); and by performing mechanistic studies to get in the majority of these studies, we used a severe model (by more proximal ligation/excision combined with an insight into the way these cells may have beneficial effects. We found that hMAPC had a more durable effect immune-deficient and low collateral reserve BalbC genetic background) and followed the effects on blood on revascularization than hAC133 + cells. In addition, un-flow recovery beyond 3 weeks of transplantation. While was observed even macroscopically in hMAPC-treated limbs, suggesting a more durable effect of this cell pop-hMAPC had a sustained and progressive effect on perfusion recovery, the initial benefit of hAC133 + cell trans-ulation in comparison with AC133 + cells. Additional studies in large animal models will contribute valuable plantation was lost at 1 month, with a regression of the capillary vessels from day 15 to day 30. Interestingly, the information for future application of hMAPC in patients. The direct contribution of hAC133 + or hMAPC to most recent clinical study with the latter cells also showed that the initially observed functional improvement was no muscle fibers has not been analyzed in the current study. However, we have previously demonstrated a limited longer significant after a 1-year follow-up (8) .
Several reasons may explain the temporary nature of contribution of mMAPC to skeletal muscle in a similar hind limb model, even though mostly due to fusion pro-the hAC133 + cell treatment effect. One may be the limited engraftment of the cells in the inflammatory ische-cesses (4). Although we cannot rule out a direct muscle (trans)differentiation of hMAPC or even hAC133 + cells, mic environment. This may be overcome by delivering the cells on a matrix scaffold, as recently demonstrated the limited engraftment suggests that muscle regeneration was mainly derived from stimulation of endogenous in ischemic rat limbs (31). As for the clinical studies, another problem relates to the functional deficit of EPC cells induced by factors secreted from hMAPC. The existence of stem/progenitor cells with broad dif-derived from patients with risk factors (12, 23) . Recent studies have revealed that these functionally deficient ferentiation potential, such as ESC, and more recently induced pluripotency cells has raised many hopes for cells can be "reeducated" by pretreatment with (angiogenic) growth factors (33). In the current study we pro-regenerative approaches, because one cell type would be sufficient to supply cells for many different damaged pose another reason for the temporal benefit of hAC133 + cells compared to the sustained effect of hMAPC (i.e., tissue types. However, in the last 5 years this paradigm has been shifting, because many studies have now a differential mechanism of revascularization). While hAC133 + mainly affected capillary growth, hMAPC had shown that the main benefit of stem cell transplantation may rather result from their trophic activity. Also in the a significant effect on collateral growth. The latter is responsible for delivering the bulk flow and hence may context of ischemia, the potential of stem cells to confer functional and perfusional improvement by the produc-represent a more crucial requirement for long-term revascularization of the ischemic tissue. tion of cytokines is by no means a new concept (18, 19) .
In our previous study (4), we pointed out that also The importance of muscle regeneration is often not considered when evaluating cell therapy studies for limb mMAPC have a beneficial effect on vessel and muscle regeneration mainly by secreting growth factors such as ischemia. However, from our earlier comparative studies, it was apparent that, even in case of a milder form of VEGF and IGF-1. Here, we show that also hMAPC secrete significant amounts of VEGF 165 , PlGF, and bFGF, ischemia, cells with a combined vascular and muscular regeneration effect, such as undifferentiated mMAPC, while hAC133 + cells did not produce these factors at levels that were detectable by our ELISA assays. Ac-had a more durable effect on limb functional recovery compared to cells with a restricted vascular regenerative cordingly, CM from hMAPC but not hAC133 + cells stimulated EC, SMC, and SkM proliferation and/or sur-effect, such as vascular predifferentiated mMAPC (4). Most likely, muscle regenerative effects are even more vival. Our failure to detect VEGF or other cytokines in hAC133 + CM may appear in conflict with a recent desirable in more severe forms of ischemia, such as in the model used in the current study. While this has not study; however, they used cells from a different source (fetal aorta versus cord blood in our study) (7) . been shown in a limb ischemia model, hAC133 + cells have been recently reported to contribute to skeletal Patients with myocardial infarction (MI) can also benefit from treatment with endothelial progenitor cells. muscle regeneration in a model of muscle injury (29). Here, there was a trend towards stimulation of muscle In fact, functional improvement has been shown after MAPC or AC133 treatment (1, 11, 21, 24) , although un-regeneration (estimated by the appearance of desminpositive regenerating fibers) following hAC133 + cell fortunately, a direct comparison between the different cell types has not been performed. In accordance with treatment; however, this did not reach statistical significance. hMAPC, on the other hand, did stimulate myo-our results in the limb ischemia model, low/absent engraftment and differentiation potential of both cell types genesis to a significant extent, confirming our previous observations (4) . Therefore, despite higher perfusion ca-have been demonstrated, suggesting that paracrine mechanisms are responsible of the benefit observed. In pacity and greater capillary density induced by day 15 in the AC133 + -treated tissues, no significant effect on fact, we have shown that secretion of angio/arteriogenic factors by MAPC are associated with revascularization muscle necrosis was observed, suggesting that the indirect effect exerted by the hMAPC in muscle regenera-of the ischemic tissue (24) . In summary, our study demonstrates that locally in-tion was critical for limb recovery. Muscle regeneration 
